Physician

Mark S Womack, M.D.

According to 2025 Medicare claims, Mark Womack, M.D. (NPI: 1689887788) practices hematology/oncology in the Chattanooga, TN-GA market, with the plurality of this provider's patient population coming from Hamilton, TN. This provider's primary affiliated billing organization is TENNESSEE ONCOLOGY PLLC (NPI: 1811955917; TIN: 621647259) and primary practice location at 37404-2744. Womack is affiliated with the Mission Health Partners, LLC (ACO ID: A2591) and Main Street Rural Health Cedar ACO LLC (ACO ID: A5502), participating under the MSSP model.

Womack's data goes back to 2015 and runs through 2024. For example, in 2024, this provider had 746 traditional Medicare patients, billed 189,301 HCPCS/CPT codes, and received $3,235,545 in Medicare payments. The top billing code was 99214 (Established patient office or other outpatient visit with moderate level of decision making, if using time, 30 minutes or more). Part D data shows 2,136 prescription claims across 371 beneficiaries totaling $6,899,783 in drug costs, led by Revlimid (Lenalidomide). DME data shows 41 claims. Open Payments data shows 21 records totaling $96,761. You can download detailed data with all billing codes (2015-2024). For more recent data, please contact us.

Over the past 10 years, this provider's Medicare Part B carrier billing has risen steadily, from $1,640,117 to $3,235,545. Similarly, Part D prescription costs have moved sharply higher in recent years, from $2,290,172 to $6,899,783. In contrast, DME billing represents a smaller volume and started with an early spike, then settled into a lower baseline, moving from $1,760 to $1,352.

Part B Carrier Billing Trend

Medicare payment trend, with N of patients and claim lines in the table.

Year	Patients	Clm Lines	Payment
2015	817	146,806	$1,640,117
2016	832	250,856	$2,257,035
2017	778	225,844	$2,139,735
2018	776	197,854	$2,444,884
2019	768	216,350	$2,565,101
2020	681	218,471	$2,956,824
2021	745	233,663	$3,706,386
2022	803	234,264	$3,764,262
2023	797	267,827	$4,598,296
2024	746	189,301	$3,235,545

Part D Events Trend

Drug cost trend, with N of patients and prescription claims in the table.

Year	Patients	Claims	Drug Cost
2015	305	2,028	$2,290,172
2016	348	2,127	$2,220,491
2017	284	1,813	$2,024,438
2018	296	1,655	$2,834,214
2019	310	1,671	$3,280,575
2020	288	1,472	$3,324,171
2021	272	1,491	$4,996,716
2022	298	1,661	$5,742,380
2023	355	2,040	$6,641,102
2024	371	2,136	$6,899,783

DME Billing Trend

Medicare payment trend, with N of patients and DME claim records in the table.

Year	Patients	Claims	Payment
2015	N/R	23	$14,585
2016	N/R	122	$19,554
2017	N/R	45	$11,368
2018	N/R	38	$6,739
2019	N/R	96	$10,290
2020	N/R	291	$89,063
2021	22	213	$73,422
2022	N/R	33	$1,170
2023	N/R	N/R	N/R
2024	N/R	41	$1,177

* / # = suppressed by CMS; 0 = reported zero; N/R = not reported or blank.

Top 5 Part B carrier billing codes in 2024

By total payments.

Code	Description	Patients	Clm Lines	Total Payment
99214	Established patient office or other outpatient visit with moderate level of decision making, if using time, 30 minutes or more	339	645	$85
G2211	Visit complexity inherent to evaluation and management associated with medical care services that serve as the continuing focal point for all needed health care services and/or with medical care services that are part of ongoing care related to a patient's	216	308	$12
80053	Blood test, comprehensive group of blood chemicals	450	1,526	$10
36415	Insertion of needle into vein for collection of blood sample	468	1,642	$9
85025	Complete blood cell count (red cells, white blood cell, platelets), automated test and automated differential white blood cell count	489	2,010	$8

Top 5 Part D drugs in 2024

By total drug costs.

Drug	Generic	Claims	Total Day Supply	Total Drug Cost
Revlimid	Lenalidomide	68	1,680	$907,810
Calquence	Acalabrutinib Maleate	61	1,830	$818,353
Xtandi	Enzalutamide	60	1,800	$765,816
Imbruvica	Ibrutinib	51	1,470	$730,067
Pomalyst	Pomalidomide	28	682	$525,028

Top 5 DME services in 2024

By Total Medicare Payment Amount.

HCPCS Code	HCPCS Description	Supplier Rental Indicator	Total Supplier Beneficiaries	Total Supplier Claims	Total Medicare Payment Amount
J8521	Capecitabine, oral, 500 mg	N	N/R	21	$820
Q0511	Pharmacy supply fee for oral anti-cancer, oral anti-emetic or immunosuppressive drug(s); for the first prescription in a 30-day period	N	N/R	20	$358

Open Payments Summary in 2024

Category	Definition	Records	Total Reported Amount	Top Related Entity
General Payments	Reported payment or transfer-of-value amount.	4	$92	Daiichi Sankyo Inc.
Research Payments	Reported research-related payment or transfer-of-value amount.	17	$96,669	Exelixis Inc.
Ownership / Investment Interests	Reported value of ownership or investment interests.	0	$0	N/R

Explore More Providers

FAQ

What Medicare data is available for Mark S. Womack, M.D.?

Tedicare shows public-source Medicare data for Mark S. Womack, M.D. (NPI 1689887788), including provider identity, specialty, market context, Medicare Part B activity, Part D prescribing, DME records, Open Payments where available, billing organization details, and ACO affiliation signals where available. Profile data covers 2015-2024, with current attribution based on 2025 claims where available.

Does Mark S. Womack, M.D. have ACO affiliation data?

Mark S. Womack, M.D. is shown with ACO affiliation data for Mission Health Partners, LLC (MSSP, ACO ID A2591) and Main Street Rural Health Cedar ACO LLC (MSSP, ACO ID A5502).

What billing organization is linked to Mark S. Womack, M.D.?

Mark S. Womack, M.D. is linked to TENNESSEE ONCOLOGY PLLC (billing NPI 1811955917) in the available physician profile data.

Does Mark S. Womack, M.D. have Open Payments data?

Mark S. Womack, M.D. has 21 connected Open Payments records in the available 2024 summary data.

Can I download physician-level Medicare data from Tedicare?

Yes. Tedicare provides sample physician export data and paid custom physician data exports for research, planning, outreach, and market analysis. Exports can include physician profile fields, market and specialty context, billing organization details, ACO affiliation signals where available, and Medicare utilization data.